Testimony, Comments, & Letters

;

Support letter to CA State Assembly Appropriations Committee for AB 2180 on cost-sharing

May 6, 2024

HIV+Hep strongly supports AB 2180. It simply requires that the copay assistance which beneficiaries receive counts towards their out-of-pocket obligations. By passing this law, California will join 20 other states (Arkansas, Arizona, Colorado, Connecticut, Delaware, Georgia, Illinois, Kentucky, Louisiana, Maine, New Mexico, New York, North Carolina, Oklahoma, Oregon, Tennessee, Texas, Washington, West Virginia, and Virginia), Puerto Rico and the District of Columbia in protecting consumers by assuring their copay assistance will count towards cost-sharing obligations.

read more

House testimony on FY25 appropriations for HIV and hepatitis programs

May 3, 2024

Our nation can eliminate both HIV and viral hepatitis, but without an infusion of new resources to accelerate our efforts, we will continue to fall short of these ambitious goals. While we realize strict spending caps are in place, increased investment – and certainly not cuts – in surveillance, education, prevention, and care and treatment will lead to further progress in reducing HIV and viral hepatitis, which include taking a syndemic approach to achieve maximum impact. The programs and funding increases detailed below are pivotal to our nation’s ability to end both these potentially deadly infectious diseases.

read more

Support for NH SB 354 relative to insurance cost-sharing calculations

Apr 29, 2024

It is a pleasure to reiterate our strong support for Senate Bill 354-FN (“relative to insurance cost-sharing calculations”) which would require health insurers and pharmacy benefit managers to include any amount paid by the enrollee or on their behalf in calculating an enrollee’s contribution to cost-sharing requirements. Now that the Senate successfully passed the bill, we are pleased that you will be holding a hearing on this important issue and that you too will pass the bill.

read more

Support for changing the NV essential health benefits benchmark plan

Apr 12, 2024

We support changing the state EHB benchmark plan to one that covers all FDA-approved tests and drugs to treat and prevent HIV, hepatitis B, hepatitis C, and opioid use. It is a timely juncture for states that wish to improve access to testing, treatment, and prevention for HIV and viral hepatitis to consider an update to a more generous EHB benchmark plan.  The recently finalized 2025 Notice of Benefit and Payment Parameters has created new opportunities for states to define what comprehensive health insurance should look like and to close gaps in coverage.

read more

Search

Categories

Tags

ACA Appropriations Biden administration CDC co-pay accumulators Congress copay copay accumulator Copay accumulators Copay assistance Cost-sharing COVID-19 Drug Pricing FDA Gay men healthcare Hepatitis Hepatitis B hepatitis C Hepatitis Prevention HHS HIV HIV Prevention Insurers Medicaid medicare Medicare Part D NAIC NIH PBM PBMs PrEP Prescription Drugs Private Insurance Ryan White Program state STDs Syringe services Testing transparency Treatment Trump administration women

Recent Testimony, Letters, Comments

Pin It on Pinterest